Vascular endothelial growth factors in cardiovascular medicine

Journal of Cardiovascular Medicine

Volumn 9, Issue 12, 2008, Pages 1190-1221

  Testa, Ugo ^a   Pannitteri, Gaetano ^b   Condorelli, Gian Luigi ^c,d  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d Istitudo di Ricovero e Cura a Carattere Scientifico Multimedia Scientific and Technology Pole   (Italy)

Author keywords

Atherosclerosis; Endothelial growth factors; Gene therapy; Heart ischemic disease

Indexed keywords

ADENOVIRUS VECTOR; ANGIOGENESIS INHIBITOR; ANGIOPOIETIN; ANGIOSTATIN; ENDOSTATIN; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 4; FUMAGILLIN; FUMAGILLOL CHLOROACETYLCARBAMATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; PLACENTAL GROWTH FACTOR; RECOMBINANT VASCULOTROPIN; VASCULOTROPIN; VASCULOTROPIN 165; VASCULOTROPIN A; VASCULOTROPIN ANTIBODY; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 2; MEMBRANE PROTEIN; PIGF PROTEIN, HUMAN; UNCLASSIFIED DRUG; VASCULOTROPIN B;

ACUTE HEART INFARCTION; ANGIOGENESIS; ARTERY DISEASE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CELL FUNCTION; CELL MATURATION; CHRONIC DISEASE; CORONARY ARTERY DISEASE; DISEASE COURSE; DRUG EFFECT; DRUG MEGADOSE; ENDOTHELIUM CELL; GENE TRANSFER; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIMB ISCHEMIA; LOW DRUG DOSE; LYMPHANGIOGENESIS; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROTEIN FAMILY; PROTEIN FUNCTION; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SINGLE DRUG DOSE; STABLE ANGINA PECTORIS; PATHOPHYSIOLOGY; PHYSIOLOGY;

CARDIOVASCULAR DISEASES; ENDOTHELIAL CELLS; HUMANS; MEMBRANE PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR B; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR D;

EID: 59449093593     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/JCM.0b013e3283117d37     Document Type: Review

References (262)

1. Pelosi E, Valtieri M, Coppola S, Botta R, Gabbianelli M, Lulli V, et al. Identification of the hemangioblast in postnatal life. Blood 2002; 100:3203-3208.
2. Kennedy M, D'Souza SL, Lynch-Kattman M, Schwantz S, Keller G. Development of the hemangioblast defines the onset of hematopoiesis in human ES differentiation cultures. Blood 2007; 109:2679-2687.
3. Zafonte MT, Liu S, Lynch-Kaffman M, Torregroza I, Benvenuto L, Kennedy M, et al. Smad1 expands the hemangioblast population within a limited developmental window. Blood 2007; 109:516-523.
4. Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971; 133:275-288.
5. Leung DW, Cochianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246:1306-1309.
6. Maglione D, Guerriero V, Viglietto G, Delli-Bovi P, Persico MG. Isolation of a human placenta cDNA encoding for a protein related to the vascular permeability factor. Proc Natl Acad Sci U S A 1991; 88:9267-9271.
7. Olofsson B, Pajusola K, Kaipainen A, Von Euler G, Jokov V, Saksela O, et al. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci U S A 1996; 93:2576-2581.
8. Jonkov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 1996; 15:290-298.
9. Anchen MG, Jeltsch C, Kukk E, Makinen T, Vitali A, Wilks AF, et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 and VEGF receptor 3. Proc Natl Acad Sci U S A 1998; 95:548-553.
10. Ramsauer M, D'Amore P. Contextual role for angiopoietins and TGF-β1 in blood vessel stabilization. J Cell Sci 2007; 120:1810-1817.
11. Gerber HP, Dixit V, Ferrara N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem 1996; 273:13313-13316.
12. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996; 380:439-442.
13. Lee S, Chen TT, Barber CL, Jordan MC, Murdock J, Desai S, et al. Autocrine vEGF signaling is required for vascular homeostasis. Cell 2007; 130:691-703.
14. Giordano FJ, Gerber HP, Williams SP, Van Bruggen N, Bunting S, Ruizlozano P, et al. A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. Proc Natl Acad Sci U S A 2001; 98:5780-5785.
15. CarmelietP, Ng YS, Nuyens D, Theilmeier G, Brusselmans K, Cornelissen I, et al. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat Med 1999; 5:495-502.
16. Arany Z, Foo SY, Ma Y, Ruas JL, Bommi-Reddy A, Girnun G, et al. HIFindependent regulation of VEGF and angiogenesis by the transcriptional activator PGC-1α. Nature 2008; 451:1008-1012.
17. De Nash AD, Baca M, Wright C, Scotney PD. The biology of vascular endothelial growth factor-B (VEGF-B). Pulm Pharmacol Ther 2006; 19:61-69.
18. BellomoD,Headrick JP, Silins GU, Paterson CA, Thomas PS, Gartside M, et al. Mice lacking the vascular endothelial growth factor-B gene (VEGFB) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia. Circ Res 2000; 86:E29-E35.
19. Saharaninen P, Tammela T, Karkkainen MJ, Alitalo K. Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. Trends Immunol 2004; 25:387-395.
20. Karkkainen MJ, Haiko P, Sainio K, Partanen J, Taipale J, Petrova TV, et al. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol 2004; 5:74-80.
21. Ristimaki A, Narko K, Enholm B, Joukov V, Alitalo K. Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C. J Biol Chem 1998; 273:8413-8418.
22. Ogawa S, Oku A, Sawano A, Yamaguchi S, Yazaki Y, Shibuya M. A novel type of vascular endothelial growth factor VEGF-E preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparinbinding domain. J Biol Chem 1998; 273:31273-31282.
23. Cébe-Suarez S, Grunewald FS, Jaussi R, Li X, Claesson-Welsh L, Spillmann D, et al. Orf virus VEGF-E NZZ promotes paracellular NRP-1/ VEGFR-2 coreceptor assembly via the peptide RPPR. FASEB J 2008; 22:3078-3086.
24. De Falco S, Gigante B, Persico MG. Structure and function of placental growth factor. Trends Cardiovasc Med 2002; 12:241-246.
25. Autiero M, Waltenberger J,Commoni D, Kranz A, Moons L,Lambrechts D, et al. Role of PLGF in the intra- and intermolecular cross-talk between the VEGF receptors Flt1 and Flk1. Nat Med 2003; 9:936-943.
26. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, DeMol M, et al. Synergism between vascular endothelial growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001; 7:575-583.
27. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsch L. VEGF receptor signaling in control of vascular function. Nat Rev Mol Cell Biol 2006; 7:359-371.
28. Gerber HP, Condorelli F, Park J, Ferrara N. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes Flt1, but not Flk-1/KDR, is up-regulated by hypoxia. J Biol Chem 1997; 272:23659-23667.
29. Fong GH, Rossant J, Gertsenstein M, Breitman ML. Role of the Flt1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995; 376:66-70.
30. Kearney JB. Vascular endothelial growth factor receptor Flt1 negatively regulates developmental blood vessel formation by modulating endothelial cell division. Blood 2002; 99:2397-2407.
31. Hiratsuka S, Minowa O, Kuno J, Noda T, Shibuya M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci U S A 1998; 95:9349-9354.
32. Seethram L, Gotoh N, Maru Y, Neufeld G, Yamaguchi S, Shibuya M. A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF. Oncogene 1995; 10:135-147.
33. Zeng H, Dvorak HF, MukhopadhyayD. Vascular permeability factor/VEGF receptor-1 downmodulates VEGF receptor 2-mediated endothelial cell proliferation, but not migration, through phosphatidylinositol 3-kinasedependent pathways. J Biol Chem 2001; 276:26969-26979.
34. Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherrer A, Liao F, et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002; 8:831-840.
35. -1+ stem cells from bone-marrow microenvironment. Nat Med 2002; 8:841-849.
36. Kendall RL, WangG,Thomas KA. Identificationofanatural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 1996; 226:324-328.
37. Kappas NC, Zeng G, Chappel JC, Kearney JB, Hazanika S, Kallianos KG, et al. The VEGF receptor Flt-1 spatially modulates Flk-1 signaling and blood vessel branching. J Cell Biol 2008; 181:847-858.
38. Levine RJ, Maynard SE, Qian C. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350:672-683.
39. Maynard SE, Min JY, Mechan J. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111:649-658.
40. TakahashiT,ShibuyaM.The 230kDa formofKDR/Flk-1 (VEGFreceptor-2) activates the PLC-gamma pathway and partially induces mitotic signals in NIH3T3 fibroblasts. Oncogene 1997; 14:2079-2089.
41. Shen BQ, Lee DY, Gerber HP, Key BA, Ferrara N, Zioncheck TF. Homologous up-regulation of KDR/Flk-1 receptor expression by vascular endothelial growth factor in vitro. JBiol Chem 1998; 273:29979-29995.
42. Gabhann FM, Popel AS. Dimerization of VEGF receptors and implications for signal transduction: a computational study. Biophys Chem 2007; 128:125-139.
43. Ruch C, Skiniotis G, Steinmetz MO, Walz T, Ballmer-Hofer K. Structure of a VEGF-VEGF receptor complex determined by electron microscopy. Nat Struct Mol Biol 2007; 14:249-250.
44. Takahashi T, Yamaguchi S, Chida K, Shibuya M. A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-γ and DNA synthesis in vascular endothelial cells. EMBO J 2001; 20:2768-2778.
45. Sakurai Y, Ohgimoto K, Kataoka Y, Yoshida N, Shibuya M. Essential role of Flk-1 (VEGF receptor-2) tyrosine residue 1173 in vasculogenesis in mice. Proc Natl Acad Sci U S A 2005; 102:1076-1081.
46. Gerber HP, McMurtrey A, Kowalski J, Yan M, Key BA, Dixit V, Ferrara N. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidyinositol 3″-kinase/AKT signal transduction pathway. J Biol Chem 1998; 273:30336-30343.
47. Granpera M, Guillermet-Guilbert J, Fankas LC, Phng LK, Cain RJ, Salpeker A, et al. Angiogenesis selectively requires rhe p110α isoform of PI3K to control endothelial cell migration. Nature 2008; 453:662-665.
48. Matsumoto T, Bohman S, Dixelius J, Berge T, Dimberg A, Magnusson P, et al. VEGF receptor-2 Y951 signaling and a role for the adaptor molecule TSAd in tumor angiogenesis. EMBO J 2005; 24:2342-2353.
49. Lamalice L, Houle F, Jourdan G, Huot J. Phosphorylation of tyrosine 1214 on VEGFR2 is required for VEGF-induced activation of Cdc42 upstream of SAPK2/p38. Oncogene 2004; 23:434-445.
50. Issbrucker K, Marti HH, Hippenstiel S, Sprimgmann G, Voswinckel R, Gaumom A, et al. p38 MAP Kinase-a molecular switch between VEGF-induced angiogenesis and vascular hypermeability. FASEB J 2003; 17:262-264.
51. Matsumoto T, Turesson I, Book M, Gerwins P, Claesson-Welsch L. p38 MAPK negatively regulates endothelial cell survival, proliferation, and differentiation in FGF2-stimulated angiogenesis. J Biol Chem 2002; 156:149-160.
52. McMullen ME, Bryant PW, Glembotscki CC, Vincent PA, Pumiglia KM. Activation of p38 has opposing effects on the proliferation and migration of endothelial cells. J Biol Chem 2005; 280:20995-21003.
53. Rousseau S, Houle F, Landry J, Huot J. p38 MAPK activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene 1997; 15:2169-2177.
54. Grosjean J, Kiriakidis S, Reilly K, Feldmann M, Peleolog E. Vascular endothelial growth factor signaling in endothelial cell survival: a role for NFκB. Biochem Biophys Res Commun 2006; 340: 984-994.
55. Duvaql M, Le Bœuf F, Huot J, Gratton JP. Src-mediated phosphorylation of Hsp90 in response to VEGF is required for VEGF Receptor-2 signaling to eNOS. Mol Biol Cell 2007; 18:4659-4668.
56. Blanes MG, Oubaha M, Rautereau Y, Gratton JP. Phosphorylation of tyrosine 801 of vascular endothelial growth factor receptor-2 is necessary for Akt-dependent endothelial nitric-oxide synthase activation and nitric oxide release from endothelial cells. J Biol Chem 2007; 282:10660-10669.
57. Somanath PR, Rozorenova OV, Chen J, Byzova TV. Akt1inendothelial cell and angiogenesis. Cell Cycle 2006; 5:512-518.
58. Ackah E. Akt1 protein kinase B is critical for ischemic and VEGF-mediated angiogenesis. J Clin Invest 2005; 115:2119-2127.
59. Chen J. Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo. Nat Med 2005; 11:1188-1196.
60. Shiojima I, Walsh K. Regulation of cardiac growth and coronary angiogenesis by the Akt/PKB signaling pathway. Genes Dev 2006; 20:3347-3365.
61. Kitamura T, Asai N, Enomoto A, Maeda K, Kato T, Ishida M, et al. Regulation of VEGF-mediated angiogenesis by the Akt/PKB substrate Girdin. Nat Cell Biol 2008; 10:329-337.
62. Eliceiri BP, Paul R, Schwartzberg PL, Hood JD, Leng J, Cheresh DA. Selective requirement for Src kinases during VEGF-induced angiogenesis and vasculature permeability. Mol Cell 1999; 4:915-924.
63. Gavard J, Gufkind JS. VEGF controls endothelial-cell permeability by promoting the β-arrestin-dependent endocytosis of VE-cadherin. Nat Cell Biol 2006; 8:1223-1234.
64. Jones CA, London NR, Chen H, Park KW, Sauvaget D, Stockton RA, et al. Robo4 stabilizes the vascular network by inhibiting pathologic angiogenesis and endothelial hyperpermeability. Nat Med 2008; 14:448-453.
65. Dumont DJ, Jussila L, Taipale J, Limboussaki A, Mustonen T, Pajusola K, et al. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science 1998; 282:946-949.
66. Wigler JT, Oliver G. Prox1 function is required for the development of the murine lymphatic system. Cell 1998; 98:769-778.
67. Tammela T, Zukada G, Wallgrad E, Murtomaki A, Suchiting S, Wirzenius M, et al. Blocking VEGF-R3 suppresses angiogenic sprouting and vascular network formation. Nature 2008; 454:656-660.
68. Petrova TV, Maikinen T, Makela TP, Saerela J, Virtanen I, Ferrele RE, et al. Lymphatic endothelial reprogramming of vascular endothelial cells by the Prox-1 homeobox transcription factor. EMBO J 2002; 21:4593-4599.
69. Dilexius J, Makinen T, Wirzenius M, Karkkainen MJ, Wenstedt C, Alitalo K, et al. Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3) heterodimerization with VEGFR-2 in primary lymphatic endothelial cells regulates tyrosine phosphorylation sites. J Biol Chem 2003; 278:40973-40979.
70. Kooi CV, Jusino MA, Perman B, Neau DB, Bellamy HD, Leahy DJ. Structural basis for ligand and heparin binding to neuropilin B domains. Proc Natl Acad Sci U S A 2007; 104:6152-6157.
71. Whitaker GB, Limberg BJ, Rosembaum JS. Vascular endothelial growth factor receptor-2 and neuropilin-1 form a receptor complex that is responsible for the differential signaling potency of VEGF (165) and VEGF (121). J Biol Chem 2001; 276:25520-25531.
72. Soker S, Takashima S, Miao HG, Neufeld G, Klagsburn M. Neuropilin-1 is expressed as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998; 92:735-745.
73. Fuh G, Garcia KC, De Vos AM. The interaction of neuropilin-1 with vascular endothelial growth factor and its receptor Flt-1. J Biol Chem 2000; 275:26690-26695.
74. 121 and regulates endothelial cell migration and sprouting. J Biol Chem 2007; 282:24049-24056.
75. Yuan L, Moynon D, Pardnaud L, Breant C, Karkkainen MJ, Alitalo K, et al. Abnormal lymphatic vessel development in neuropilin-2 mutant mice. Development 2002; 129:4797-4806.
76. Guttmann-Raviv N, Shraga-Heled N, Varshavsky A, Guimares-Sternberg C, Kessler O, Neufeld G. Semaphirin-3A and semaphorin-3F work together to repel endothelial cells and to inhibit their survival by induction of apoptosis. J Biol Chem 2007; 282:26294-26305.
77. Serini G, Valdembri D, Zenivan S, Morterra G, Burkhardt C, Caccavari F, et al. Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function. Nature 2003; 424:391-398.
78. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, et al. Isolation of angiopoietin-1, a ligand for the Tie-2 receptor, by secretiontrap expression cloning. Cell 1996; 87:1161-1169.
79. Kim KT, Choi HH, Steimetz MO, Maco B, Kammerer RA, Ahn SY, et al. Oligomerization and multimerization is critical for angiopoietin-1 to bind and phosphorylate Tie 2. J Biol Chem 2005; 280:20126-20131.
80. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegaud SJ, Rodriejewski C, et al. Angiopoietin-2, a natural antagonist for Tie-2 that disrupts in vivo angiogenesis. Science 1997; 277:55-60.
81. Suri C, Jones PF, Bartunkova S, Maisonpierre PC, Davis S, Sato TN, Yancopoulos GD. Requisite role of angiopoietin-1, a ligand for the Tie-2 receptor, during embryonic angiogenesis. Cell 1996; 87:1171-1180.
82. Brindle NPJ, Saharinen P, Alitalo K. Signaling and functions of angiopoietin-1 in vascular protection. Circulation Res 2006; 98:1014-1023.
83. Fiedler U, Schrpfnecker M, Koidl S, Hegen A, Grunow V, Schmidt JM, et al. The Tie-2 ligand angiopoietin-2 is stored in and is rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood 2004; 103:4150-4156.
84. Fiedler U, Reiss Y, Scharpenecker M, Grumow V, Koidl S, Thurston G, et al. Angiopoietin-2 sensitizes endothelial cells to TNF-α and has a crucial role in the induction of inflammation. Nat Med 2006; 12:235-239.
85. Pantanen J, Armstrong E, Makela TP, Korhonen J, Sandberg M, Renkonen R, et al. A novel endothelial cell surface receptor tyrosine kinase with extracellular epidermal growth factor homology domains. Mol Cell Biol 1992; 12:1698-1707.
86. Macdonald P, Progias P, Ciani B, Patel S, Mayer U, Steinmetz RA, et al. Structure of the extracellular domain of Tie receptor tyrosine kinases and localization of the angiopoietin-binding epitope. J Biol Chem 2007; 281:28408-28414.
87. Barton WA, Tzvetkova-Robev D, Miranda EP, Kolev MV, Rajashankar KR, Himanen JP, et al. Crystal structures of the Tie3 receptor ectodomain and the angiopoietin-2-Tie2 complex. Nat Struct Mol Biol 2006; 13:524-532.
88. Dumont D, Gradwahl G, Fong G, Puri M, Gentsenstein M, Auerbach A, Breitman M. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, Tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev 1994; 8:1897-1909.
89. Sato T, Tozawa Y, Deutsch U, Wolburg H, Risau W, Qin Y. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 1995; 376:70-74.
90. Puri MC, Rossant J, Alitalo K, Bernstein A, Partanen J. The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells. EMBO J 1995; 14:5884-5891.
91. Partanen J, Puri MC, Schwartz L, Fischer KD, Bernstein A, Rossant J. Cell autonomous functions of the receptor tyrosine kinase TIE in a late phase of angiogenic capillary growth and endothelial cell survival during murine development. Development 1996; 122:30113-33021.
92. De Busk LM, Hallahan DE, Lin PC. Akt is a major angiogenic mediator downstream of the Ang1/Tie2 signaling pathway. Exp Cell Res 2004; 298:167-177.
93. Kim I, Kim JN, Kim JH, Kwak HJ, Koh GY. Angiopoietin-1 regulates endothelial cell survival through the phosphatydilinositol 3″-kinase-Aky signal transduction pathway. Circ Res 2000; 86:24-29.
94. Dominguez MG, Hughes VC, Pan L, Simmons M, Daly C, Anderson K, et al. Vascular endothelial tyrosine phosphatase (VE-PTP)-null mice undergo vasculogenesis, but die embryonically because of defects in angiogenesis. Proc Natl Acad Sci U S A 2007; 104:3243-3248.
95. Saharinen P, Eklund L, Miettinen J, Wirkkala R, Anisimov A, Winderlich M, et al. Angiopoietins assemble distinct Tie2 signaling complexes in endothelial cell-cell and cell-matrix contacts. Nat Cell Biol 2008; 10:527-537.
96. Saharaninen K, Kerkela N, Ekman M, Marron N, Brindle GM, Lee H, et al. Multiple angiopoietin recombinant proteins activate the Tie-1 receptor tyrosine kinase and promote its interaction with Tie-2. J Cell Biol 2005; 169:239-243.
97. Chan B, Yuan HT, Karumanchi SA, Sukhatma VP. Receptor tyrosine kinase Tie-1 overexpression in endothelial cells upregulates adhesion molecules. Biochem Biophys Res Commun 2008; 371:475-479.
98. Lobov IB, Renard RA, Papadopoulos N, Gale NW, Thurston G, Yancopoulos GD, Wiegaud SJ. Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator ofangiogenic sprouting. Proc Natl Acad Sci U S A 2007; 104:3219-3224.
99. Hellstrom M, Pheng LK, Hofmann J, Wallgrand E, Coultas L, Lindblom P, et al. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 2007; 445:776-780.
100. Williams CK, Li JL, Mung M, Harris AL, Tosato G. Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cells. Blood 2006; 107:931-939.
101. Trindade A, Kumar SR, Scehnet JS, Lopes-da-Costa L, Becker J, Jiang W, et al. Overexpression of Delta-like 4 induces arterializations and attenuates vessel formation in developing mouse embryos. Blood (in press).
102. Scehnet J, Jiang W, Kumar R, Krasnoperov V, Trindade A, Benedito R, et al. Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. Blood 2007; 109:4753-4760.
103. Limbourg A, Ploom M, Elligsen D, Sorensen I, Ziegelhoeffer AG, Gossler A, et al. Notch ligand Delta-Like1 is essential for postnatal arteriogenesis. Circ Res 2007; 100:363-371.
104. Le Couter J, Kowalski J, Foster J, Hass P, Zhang Z, Dillord-Telm L, et al. Identification of an angiogeneic mitogen selective for endocrine gland endothelium. Nature 2001; 412:877-884.
105. Le Couter J, Liu R, Ferrara N. Endocrine gland-derived VEGF and the emerging hypothesis of organ-specific regulation of angiogenesis. Nat Med 2002; 8:913-917.
106. Shojaei F, Wu X, Zhang C, Yu L, Liang XH, Yao J, et al. Bv8 regulates myeloid-cell dependent tumor angiogenesis. Nature 2007; 450:825-831.
107. Bussolino F, Mantovani A, Persico G. Molecular mechanisms of blood vessel formation. Trends Biochem Sci 1997; 22:251-256.
108. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994; 79:1157-1164.
109. 3 integrin, osteopontin and thrombin. Am J Pathol 1997; 149:293-305.
110. Soldi R, Mitola S, Strasly M, Defilippi P, Tarone G, Bussolino F. Role of aVb3 integrin in the activation of vascular endothelial growth factor receptor-2. EMBO J 1999; 18:882-892.
111. Serini G, Napione L, Arese M, Bussolino F. Besides the adhesion: new perspectives of integrin functions in angiogenesis. Cardiovasc Res 2008; 78:213-222.
112. Potente M, Ghaeni L, Baldessari D, Mostolavsky R, Rossig L, Dequiedt F, et al. SIRT1 controls endothelial angiogeneic functions during vascular growth. Genes Dev 2007; 21:2644-2658.
113. Potente M, Urbich C, Sasaki KI, Hoffmann WK, Heeschen C, Aichen A, et al. Involvement of Foxo transcription factors in angiogenesis and postnatal neovascularization. J Clin Invest 2005; 115:2382-2392.
114. Hayashi H, Sano H, Seo S, Kume T. The Fox2 transcription factor regulates angiogenesis via induction of integrin beta3 expression. J Biol Chem (in press).
115. Hatashi H, Hume T. Foxo transcription factors directly regulate Dll4 and Hey2 expression by interacting with the VEGF-Notch signaling pathways. PLoS ONE 2008; 3:1-9.
116. Maharaj AS, Saint-Geniez M, Maldonado AE, D'Amore PA. Vascular endothelial growth factor localization in the adult. Am J Pathol 2006; 168:639-648.
117. Rissanen TT, Vajanto I, Hiltunen MO, Rutanen J, Kettunen MI, Niemi M, et al. Expression of vascular endothelial growth factor receptor-2 (KDR) in ischemic skeletal muscle and its regeneration. Am J Pathol 2002; 160:1393-1403.
118. Grunewald M, Avraham I, Dor Y, Bachar-Lustig E, Itin A, Yung S. VEGF-induced adult neovascularization recruitment, retention, and role of accessory cells. Cell 2006; 124:175-189.
119. Langheinrich AC, Kampsculte M, Buch T, Bohle RM. Vasa vasorum and atherosclerosis. Quid novi? Thromb Haemost 2007; 97:873-879.
120. Heistad DD, Marcus ML. Role ofvasa vasorum innourishmentofthe aorta. Blood Vessels 1979; 16:225-238.
121. Isner JM. Cancer and atherosclerosis: the broad mandate of angiogenesis. Circulation 1999; 99:1653-1655.
122. Jeziorska M, Wooley DE. Neovascularization in early atherosclerotic lesions of human carotid arteries: its potential contribution to plaque development. Hum Pathol 1999; 30:919-925.
123. Fleiner M, Kummer M, Mirlacher M, Sauter G, Cathomas G, Krapf R, et al. Arterial neovascularization and inflammation in vulnerable patients: early and late signs of symptomatic atherosclerosis. Circulation 2004; 110:2843-2850.
124. Depre C, Havaux X, Wijns W. Neovascularization in human coronary atherosclerotic lesions. Cathet Cardiovasc Diagn 1996; 39:215-220.
125. Mofidi R, Crotty TB, McCarthy P, Sheean SJ, Mehigan D, Keaveny TV. Association between plaque instability, angiogenesis and symptomatic carotid occlusive disease. Br J Surg 2001; 88:945-950.
126. Carter A, Murphy MO, Turner NJ, Halka AT, Ghosh J, Serracino-Inglott F, et al. Intimal neovascularization is a prominent feature of atherosclerotic plaques in diabetic patients with critical limb ischemia. Eur J Endovasc Surg 2007; 33:319-324.
127. O'Brien KD, Allen MD, McDonald TM, Chait AA, Harlem JM, Fishbein D, et al. Vascular cell adhesion molecule-1 is expressed in human coronary atherosclerotic plaques. J Clin Invest 1993; 92:945-951.
128. O'Brien KD, McDonald TM, Chait A, Allen MD, Alpers CE. Neovascular expression of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in human atherosclerosis and their relation to intimal leukocyte content. Circulation 1996; 93:672-682.
129. Moreno PR, Purushothaman KR, Sirol M, Levy AP, Fuster V. Neovascularization in human atherosclerosis. Circulation 2005; 113:2245-2252.
130. Moreno PR, Purushothaman KR, Fuster V, Echeverri D, Truszczynske H, Sharma SK, et al. Plaque neovascularization is increased in ruptured atherosclerotic lesions in human aorta: implications for plaque vulnerability. Circulation 2004; 110:2032-2038.
131. Inoue M, Itoh H, Uada M, Naruko T, Kojima A, Komatsu R, et al. Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions. Circulation 1998; 98:2108-2116.
132. Couffindhal T, Kearney M, Witzembichler B, Chen D, Murohara T, LoSordo DW, et al. Vascular endothelial growth factor (VEGF/VPF) in normal and atherosclerotic human arteries. Am J Pathol 1997; 150:1673-1685.
133. Belgore F, Blann A, Neil D, Ahmed AS, Hip GYH. Localisation of members of the vascular endothelial growth factor (VEGF) family and their receptors in human atherosclerotic arteries. J Clin Pathol 2004; 57:266-272.
134. Sluimer JC, Gasc JM, Van Wanroij J, Kisters N, Groenewg M, Gelpke MD, et al. Hypoxia, hypoxia-inducible transcription factor, and macrophages in human atherosclerotic plaques are correlated with intraplaque angiogenesis. J Am College Cardiol 2008; 51:1258-1265.
135. Bjorheden T, LevinM,Evaldsson M,Wiklund O. Evidenceofhypoxic areas within the arterial wall in vivo. Arterioscler Thromb Vasc Biol 1999; 19:870-876.
136. Osada-Oka M, Ikeda T, Imaoka S, Akiba S, Sato T. VEGF-enhanced proliferation under hypoxia by an autocrine mechanism in human vascular smooth muscle cells. J Athroscler Thromb 2008; 15:26-33.
137. Hashiguchi T, Arimura K, Matumoro K, Otsuka R, Watanabe O, Jonosono M, et al. Highly concentrated vascular endothelial growth factor in platelets in Crow-Fukase syndrome. Muscle Nerve 2000; 23:1051-1056.
138. Banks RE, Forbes MA, Kinsey SE, Stanley A, Ingham E, Walters C, et al. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer 1998; 77:956-964.
139. Gunsilius E, Petzer A, Stockammer G, Nussbaumer W, Schumacher P, Clausen J, et al. Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral blood. Oncology 2000; 58:169-174.
140. Blann AD, Belgore FM, Constants J, Conri C, Lip GY. Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate. Am J Cardiol 2001; 87:1160-1163.
141. Alber HF, Frick M, Dulak J, Dorler J, Zwieck RH, Dichtl W. Vascular endothelial growth factor (VEGF) plasma concentrations in coronary artery disease. Heart 2005; 91:365-366.
142. Tsai WC, Li YH, Huang YY, Lin CC, Chao TH, Chen JH, et al. Plasma vascular endothelial growth factor is a marker for early vascular damage in hypertension. Clin Sci 2005; 109:39-43.
143. Trapé J, Morales C, Molina R, Filella X, Marcos JM, Salinas R, Franquesca J. Vascular endothelial growth factor serum concentrations in hypercholesterolemic patients. Scad J Clin Lab Invest 2006; 66:261-268.
144. Hojo Y, Ikeda U, Maeda Y, Takabashi M, Takizawa T, Okada M, et al. Interaction between human monocytes and vascular smooth muscle cells induces vascular endothelial growth factor expression. Atherosclerosis 2000; 150:63-70.
145. Inouse M, Itoh H, Tanaka T, Chun TL, Doi K, Fukunaga Y, et al. Oxidized LDL regulates vascular endothelial growth factor expression in human macrophages and endothelial cells through activation of peroxisome proliferator-activated receptor-gamma. Arterioscler Thromb Vasc Biol 2001; 21:560-566.
146. Ramos MA, Kazuya M, Esaki T, Miura S, Satake S, Asai T, et al. Induction of macrophage VEGF in response to oxidized LDL and VEGF accumulation in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1998; 18:1188-1196.
147. Kimura K, Hashiguchi T, Deguchi T, Horimouchi S, Uto T, Owu H, et al. Serum VEGF as a prognostic factor of atherosclerosis. Atherosclerosis 2007; 194:182-188.
148. Eaton CB, Gramling R, Parker DR, Roberts MB, Lu B, Ridker PM. Prospective association of vascular endothelial growth factor-A (VEGF-A) with coronary heart disease mortality in Southeastern New England. Atherosclerosis 2008. [Epub ahead of print]
149. Chittenden TW, Sherman JA, Xiang F, Hall AE, Lanahan AA, Taylor JM, et al. Transcriptional profilingincoronary artery disease: indications for novel markers of coronary collateralization. Circulation 2006; 114:1811-1820.
150. Pugh CW, Rattcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003; 9:677-684.
151. Werner GS, Jandt E, Krack A, Schwartz G, Mutschke O, Kuethe F, et al. Growth factors in the collateral circulation of chronic total coronary occlusions: relation to duration of occlusion and collateral function. Circulation 2004; 110:1940-1945.
152. Lambiase PD, Edwards RJ, Anthopoulos P, Rahman S, Meng YG, Bucknall CA, et al. Circulating humoral factors and endothelial progenitor cells in patients with differing collateral support. Circulation 2004; 109:2986-2992.
153. Fleisch M, Billinger M, Eberli FR, Garachemani AR, Meier B, Seiler C. Physiologically assessed coronary collateral flow and intracoronary growth factor concentrations in patients with 1- to 3-vessel coronary artery disease. Circulation 1999; 100:1945-1950.
154. Weihrauch D, Tessmer J, Warltier DC, Chilian VM. Repetitive coronary artery occlusions induce release of growth factors into myocardial interstitium. Am J Physiol 1998; 275 (Suppl):H969-H976.
155. Briguori C, Testa U, Colombo A, Petrucci E, Condorelli G, Airoldi F, et al. Relation of various plasma growth factor levels in patients with stable angina pectoris and total occlusion of a coronary artery to the degree of coronary collaterals. Am J Cardiol 2006; 97:472-476.
156. Makano T, Nakashima V, Yonemitsu Y, Sumiyoshi S, Chen VX, Ataishima V, et al. Angiogenesis and lymphangiogenesis and expression of lymphangiogenic factors in the atherosclerotic intima of human coronary arteries. Hum Pathol 2005; 36:330-340.
157. Schmeisser A, Christoph M, Augstein A, Marquetant R, Kasper M, Braun-Dullaeus RC, et al. Apoptosis of human macrophages by Flt-4 signaling: implications for atherosclerotic plaque pathology. Card Res 2006; 71:774-784.
158. Rutanen J, Leppenen P, Tuomitso TT, Rissanen TT, Hytunen MQ, Vajanto I, et al. Vascular endothelial growth factor-D expression in human atherosclerotic lesions. Cardiovasc Res 2003; 59:971-979.
159. Moulton KS, Heller E, Konerding MA, Flynn E, Palinski W, Folkman J. Angiogenesis inhibitors endostatin or TNP-40 reduce intimal neovascularization and plaque growth in apolipoprotein-E-deficient mice. Circulation 1999; 99:1726-1732.
160. Moulton KS, Vakili K, Zurakowski D, Soliman M, Butterfield C, Sylvin E, et al. Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Acad Sci U S A 2003; 100:4736-4741.
161. Celletti FL, Waugh JM, Amabile PG, Brendolan A, Hilfiken PR, Dake MD. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 2001; 7:425-429.
162. Petrovan RJ, Kaplan CD, Reisfeld RA, Curtiss LK. DNA vaccination against VEGF receptor reduces atherosclerosis in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 2007; 27:1095-1102.
163. Hauer AD, Van Puijvelde GH, Peterse N, De Vos P, Van Weel V, Van Wanrooij JA, et al. Vaccination against VEGFR2 attenuates initiation and progression of atherosclerosis. Arterioscler Thromb Vasc Biol 2007; 27:2050-2057.
164. Usui R, Shibuya M, Ishibashi S, Maru Y. Ligand-independent activation of vascular endothelial growth factor receptor 1 by low-density lipoprotein. EMBO Rep 2007; 8:1155-1161.
165. Zimman A, Mouillesseaux KP, Le T, Gharavi NM, Ryvkin A, Graeber TG, et al. Vascular endothelial growth factor receptor 2 plays a role in the activation of aortic endothelial cells by oxidized phospholipids. Arterioscler Thromb Vasc Biol 2007; 27:332-338.
166. Sotiriou SN, Oriova VV, Al-Fakhri N, Ihanus E, Economopoulou M, Isermann B, et al. Lipoprotein(a) in atherosclerotic plaques recruits inflammatory cells through interaction with Mac-1 integrin. FASEB J 2006; 20:559-561.
167. Leppanen P, Kouta S, Kholova I, Eriksson U, Alitalo K, Herttuala S. Gene transfers of VEGF-A, VEGF-B, VEGF-C and VEGF-D have no effects on atherosclerosis in hypercholesterolemic LDL-receptor/ApoB48-deficient mice. Circulation 2005; 112:1347-1352.
168. Luttun A, Tiwa M, Moons L, Wu Y, Angelillo-Scherrer A, Liao F, Nagy JA, et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002; 8:831-840.
169. Khurana R, Moons L, Shafi S, Luttun A, Martin JF, Carmeliet P, Zachary L. Placental growth factor (PLGF) promotes atherosclerosis intimal thickening and macrophage accumulation. Circulation 2005; 111:2828-2836.
170. Herttuala SY, Rissanen T, Vajanto I, Hartikainen J. Vascular endothelial growth factors. Biology and current status of clinical applications in cardiovascular medicine. J Am Coll Cardiol 2007; 49:1015-1026.
171. Howell WM, Ali S, Rose-Zerilli MJ, Ye S. VEGF polymorphisms and severity of atherosclerosis. J Med Genet 2005; 42:485-490.
172. Kolodgie FD, Narula J, Yuan C, Burke AP, Finn AV, Virmani R. Elimination of neoangiogenesis for plaque stabilization. J Am Coll Cardiol 2007; 49:2093-2101.
173. Doyle B, Caplice N. Plaque neovascularization and antiangiogenic therapy for atherosclerosis. J Am Coll Cardiol 2007; 49:2073-2080.
174. Steinbrook R. The price of sight: ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med 2006; 355:1409-1412.
175. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other intestinal disorders. N Engl J Med 1994; 331:1480-1487.
176. Liinamaa MJ, Savolainen MJ. High vitreous concentration of vascular endothelial growth factor in diabetic patients with proliferative retinopathy using statins. Ann Med 2008; 40:209-214.
177. Keuwin W, Hooker A, Spilker M, Vicini P, Ferguson M, Hatsukami T, et al. Quantitative magnetic resonance imaging analysis of neovasculature volume in carotid atherosclerotic plaque. Circulation 2003; 107:851-856.
178. Winter PM, Marawski AM, Coruthers SD, Furhop RW, Zhang H, Williams TA, et al. Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta 3-integrin-targeted nanoparticles. Circulation 2003; 108:2270-2274.
179. Kampaschulze A, Ferguson MS, Kerwin WS, Polissar NL, Javik GP, Isaac C, et al. Differentiation of intraplaque versus juxtaluminal hemorrhage/ thrombus in advanced human carotid atherosclerotic lesions by in vivo magnetic resonance imaging. Circulation 2004; 110:3239-3244.
180. Takaya N, Yuan C, Chu B, Saam T, Polissar NL, Javik GP, et al. Presence of intraplaque hemorrhage stimulates progression of carotid atherosclerotic plaques: a high-resolution magnetic resonance imaging study. Circulation 2005; 111:2768-2775.
181. Takaya N, Yuan C, Chu B, Saam T, Underhill H, Cai J, et al. Association between carotid plaque characteristics and subsequent ischemic cerebrovascular events: a prospective assessment with MRI-initial results. Stroke 2006; 37:818-823.
182. Kietselaer BI, Reutelingsperger CP, Heidendal GA, Daemen MJ, Mess WH, Hofstra L, et al. Noninvasive detection of plaque instability with use of radiolabeled annexin A5 in patients with carotid-artery atherosclerosis. N Engl J Med 2004; 350:1472-1473.
183. Winter PM, Neubauer AM, Caruthers SD, Harris TD, Robertson JD, Williams TA, et al. Endothelial alpha(v) beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler Thromb Vasc Biol 2006; 26:2103-2109.
184. Wickline SA, Neubauer AM, Winter PM, Caruthers SD, Lanza GM. Molecular imaging and therapy of atherosclerosis with targeted nanoparticles. J Magn Reson Imaging 2007; 25:667-680.
185. Epstein SE, Stabile E, Kinnaizd T, Lee CW, Clarijo L, Barrett MS. Janus phenomenon. The interrelated tradeoffs inherent in therapy designed to enhance collateral formation and those designed to inhibit atherogenesis. Circulation 2004; 109:2826-2831.
186. Sasayama S, Fujita M. Recent insights into coronary collateral circulation. Circulation 1992; 85:1197-1204.
187. Sabia PJ, Powers ER, Ragosta M, Sarembrock IJ, Burwell LR, Kaul S. An association between collateral blood flow and myocardial viability in patients with recent myocardial infarction. N Engl J Med 1992; 327:1825-1831.
188. Schape W, Ipo WD. Molecular mechanisms of coronary collateral vessel growth. Circ Res 1996; 79:911-919.
189. Waltenberger J. Modulation of growth factor action. Clinical implications for the treatment of vascular disease. Circulation 1997; 96:4083-4094.
190. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359:843-845.
191. Li J, Brown LE, Hibberd MG, Grossman JD, Morgan JP, Simons M. VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis. Am J Physiol 1996; 270:H1803-H1811.
192. Banai S, Seweiki D, Pinson A, Chandra M, Lazarovici G, Keshet E. Upregulation of vascular endothelial growth factor expression induced by myocardial ischemia: implications for coronary angiogenesis. Cardiovasc Res 1994; 28:1176-1179.
193. Kranz A, Mayr U, Frank H, Waltenberger J. The coronary endothelium: a target for VEGF. Human coronary artery endothelial cells express functional receptors for VEGF in vitro and in vivo. Lab Invest 1999; 79:985-991.
194. Waltenberger J, Mayr U, Pentz S, Hombach V. Functional upregulation of the vascular endothelial growth factor receptor KDR by hypoxia. Circulation 1996; 94:1647-1654
195. Lee SH, Wolf PL, Escudero R, Deutsch R, Jamleson SW, Thetfetwelte PA. Early expression of angiogenesis factors in acute mayocardial ischemia and infarction. N Engl J Med 2000; 342:626-633.
196. Pannitteri G, Petrucci E, Testa U. Coordinate release of angiogenic growth factors after acute myocardial infarction: evidence for a two-wave production. J Cardiovasc Med 2006; 7:872-879.
197. Pannitteri G, Marino B, Campa PP, Martucci R, Testa U, Peschle C. Interleukins 6 and 8 as mediators of acute phase response in acute myocardial infarction. Am J Cardiol 1997; 80:622-625.
198. Hojo Y, Ikeda U, Zhu Y, Okada M, Ueno S, Arakawn H, et al. Expression of vascular endothelial growth factor in patients with acute myocardial infarction. J Am Coll Cardiol 2000; 35:968-973.
199. Heeschen C, Dimmeler S, Hamm CW, Boersma E, Zeiher AM, Simoons ML. Prognostic significance of angiogenic factor serum levels in patients with acute coronary syndromes. Circulation 2003; 107:524-530.
200. Seko Y, Imai Y, Suzuki S, Hamijukkokju S, Hayasaki K, Sakomura Y, et al. Serum levels of vascular endothelial growth factor in patients with acute myocardial infarction undergoing reperfusion therapy. J Clin Sci 1997; 92:453-454.
201. Kawamoto A, Kawata H, Akai Y, Katsuyama Y, Takase E, Sasaki Y, et al. Serum levels of VEGF and FGF in the subacute phase of myocardial infarction. Int J Cardiol 1998; 67:47-54.
202. Soeki T, Tamura Y, Shinohara H, Tanaka H, Bando K, Fukuda N. Serial changes in serum VEGF and HGF in patients with acute myocardial infarction. Int J Cardiol 2000; 93:168-174.
203. Soeki T, Tamura Y, Shinohara H, Tanaka H, Bando K, Fukuda N. Role of circulating vascular endothelial growth factor and hepatocyte growth factor in patients with coronary artery disease. Heart Vessels 2000; 15:105-111.
204. Yin R, Feng J, Chen D, Wu H. Serum levels of vascular endothelial growth factor in patients with angina pectoris and acute myocardial infarction. Chin Med Sci J 2000; 15:205-209.
205. Krank A, Rau C, Kochs M, Waltenberger J. Elevation of vascular endothelial growth factor-A serum levels following acute myocardial infarction: evidence for its origin and functional significance. J Mol Cell Cardiol 2000; 32:65-72.
206. Chung NAY, Lydakis C, Belgore F, Blann AD, Lip GY. Angiogenesis in myocardial infarction. An acute or chronic process? Eur Heart J 2002; 23:1604-1608.
207. Gerrah R, Tshori S, Gilson D. Pericardial fluid and serum VEGF in response to different types of heparin treatment. Int J Cardiol 2004; 94:193-196.
208. Weis S, Shintani S, Weber A, Kirchmair R, Wood M, Cravens A, et al. Src blockade stabilizes a Flk/cadherin complex, reducing edema and tissue injury following myocardial infarction. J Clin Invest 2004; 113:885-894.
209. Seko Y, Fukuda S, Nagai R. Serum levels of endostatin, vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in patients with acute myocardial infarction undergoing early reperfusion therapy. Clin Sci 2004; 106:439-442.
210. Shimada Y, Yoshiyama M, Jissho S, Kamimori K, Nakamura Y, Iida H, et al. Hepatocyte growth factor production may be related to the inflammatory response in patients with acute myocardial infarction. Circ J 2002; 66:253-256.
211. Lee KW, Lip G, Blann AD. Plasma angiopoitin-1, angiopoietin-2, angiopoietin receptor Tie-2 and vascular endothelial growth factor levels in acute coronary syndromes. Circulation 2004; 110:2355-2360.
212. Sandhu R, Teichert-Kuliszewska K, Nag S, Proteau G, Robb MJ, Campbell AI, et al. Reciprocal regulation of angiopoietin-1 and angiopoietin-2 following myocardial infarction in the rat. Cardiovasc Res 2004; 64:115-124.
213. Van Weel V, Seghers L, De Vries MR, Kuiper EJ, Schlingemann RO, Bajema IM, et al. Expression of vascular endothelial growth factor, stromal cell-derived factor-1, and CXCR4 in human limb muscle with acute and chronic ischemia. Atheroscler Thromb Vasc Biol 2007; 27:1426-1432.
214. Gaffney MM, Hynes SO, Barry F, O'Brien T. Cardiovascular gene therapy: current status and therapeutic potential. Br J Pharmacol 2007; 152:175-188.
215. Yu J, Lei L, Liang Y, Hinh L, Hickey RP, Huang Y, et al. An engineered VEGF-activating zinc finger protein transcription factor improves blood flow andlimb salvageinadvanced-agemice.FASEB J2006;20:479- 481.
216. Zentilin L, Tafuro S, Zacchigna S, Arsic N, Pattarini L, Sinigaglia M, et al. Bone marrow mononuclear cells are recruited to the sites of VEGF-induces neovascularization, but are not incorporated into the newly formed vessels. Blood 2006; 107:3546-3554.
217. Yoon Y, Maruyama T, Graveraux E, Tkebuchara T, Silver M, Curry C, et al. VEGF-C gene therapy augments postnatal lymphangiogenesis and ameliorates secondary lymphedema. J Clin Invest 2003; 111:717-725.
218. Saito Y, Nakagami H, Marishita R, Takami Y, Kikuchi Y, Hayashi H, et al. Transfection of human hepatocyte growth factor gene ameliorates secondary lymphedema via promotion of lymphangiogenesis. Circulation 2006; 114:1177-1184.
219. Fujita M, Ishihara M, Shimizu M, Obara K, Nakamura S, Kanatani Y, et al. Therapeutic angiogenesis induced by controlled release of fibroblast growth factor-2 from injectable chitosan/nonanticoagulant heparin hydrogel in a rat hindlimb ischemia model. Wound Rep Reg 2007; 15:58-65.
220. Makinen K, Manninen H, Hedman M, Matsi P, Mussalo H, Althava E, et al. Increased vascularity detected by digital subtraction angiography after gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study. Mol Ther 2002; 6:127-133.
221. Rajagopalan S, Mahler ER, Lederman RJ, Saucedo J, Mendelshon FO, Olin J, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003; 108:1933-1938.
222. Kusumanto YH, Weel W, Mulder NH, Smit AJ, Van Den Dungen JJ, Hooymans JM, et al. Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double blind randomized trial. Hum Gene Ther 2006; 17:683-691.
223. Baumgartner I. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998; 97:1114-1123.
224. Dellian M, Witwer BP, Salehi HA, Yuan F, Jain RK. Quantitation and physiologic characterization of angiogenic vessels in mice: effect of basic fibroblast growth factor, vascular endothelial growth factor/vascular permeability factor, and host microenvironment. Am J Pathol 1996; 149:59-71.
225. BekeredjianR, Chen S, Frenkel PA, Grayburn PA, Shohet RV. Ultrasound-targeted microbubble destruction can repeatedly direct highly specific plasmid expression to the heart. Circulation 2003; 108:1022-1026.
226. Bekeredjian R, Grayburn PA, Shohet RV. Use of ultrasound contrast agents for gene or drug delivery in cardiovascular medicine. J Am Coll Cardiol 2005; 45:329-335.
227. 165 plasmid gene delivery to chronically ischemic skeletal muscle. Circ Res 2007; 101:295-303.
228. Losordo DW, Vale PR, Symes JF, Dunnington CH, Esakof DD, Maysky M, et al. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 1998; 98:2800-2804.
229. Fortuin FD, Vale P, Losordo DW, Symes J, DeLaria GA, Tyner JJ, et al. One-year follow-up of direct myocardial gene transfer of vascular endothelial growth factor-2 using naked plasmid deoxyribonucleic acid by way of thoracotomy in no-option patients. Am J Cardiol 2003; 92:436-439.
230. Reilly JP, Grise MA, Fortuin FD, Vale PR, Schaer GL, Lopez J, et al. Longterm (2-year) clinical events following transthoracic intramyocardial gene transfer of VEGF-2 in no-option patients. J Int Cardiol 2005; 18:27-31.
231. Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ, et al. The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 2003; 107:1359-1365.
232. Hedman M, Martikainen J, Syvanne M, Stiemwall J, Hedman A, Kivela A, et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 2003; 107:2677-2683.
233. Kastrup J, Jogersen E, Ruck A, Tagi K, Glogar D, Ruzyllo W, et al. Direct intramyocardial plasmid vascular endothelial growth factor-A165 hene therapy in patients with stable severe angina pectoris. A randomized double-blind placebo-controlled study: the Euroinject One Trial. J Am Coll Cardiol 2005; 45:982-988.
234. Simons M, Annex BH, Lahman RJ, Kleiman N, Henry T, Dauerman H, et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomizeed, controlled clinical trial. Circulation 2002; 105:788-793.
235. Grines CL, Watkins MW, Helmer G, Penny W, Brinker J, Marmur JD, et al. Angiogenic gene therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002; 105:1291-1297.
236. Grines CL, Watkins MW, Mahmarian JJ, Iskandrian AE, Rade JJ, Marott P, et al. A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J Am Coll Cardiol 2003; 42:1339-1347.
237. Stewart DJ, Hilton JD, Arnold JM, Gregoire J, Rivard A, Archer SL, et al. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) versus maximum medical treatment. Gene Ther 2006; 13:1503-1511.
238. Lederman RJ, Mendelsohn FO, Anderson RD, Saucedo JF, Tenaglia AN, Hermiller JB, et al. Therapeutic angiogenesis with recombinant growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised study. Lancet 2002; 359:2053-2058.
239. 165 plasmid followed by granulocyte-colony stimulating factor to induce angiogenesis in patients with severe chronic ischaemic heart disease. Eur Heart J 2006; 27:1785-1792.
240. Wang Y, Ripa RS, Jorgensen E, Hesse B, Mortensen S, Kastrup J. Mobilization of haematopoietic and nonhaematopoietic cells by granulocyte-colony stimulating factor and vascular endothelial growth factor gene therapy in patients with stable severe coronary artery disease. Scand Cardiovasc J 2007; 8:1-8.
241. Giordano FJ, Ping P, McKirnan MD, Nozaki S, De Maria AS, Dillmann WH, et al. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat Med 1996; 2:534-539.
242. Henry TD, Grines CL, Watkins MW, Dib N, Barbean G, Moreadith R, et al. Effects of Ad5FGF-4 in patients with angina. J Am Coll Cardiol 2007; 50:1038-1046.
243. Visconti RP, Richardson CD, Sato TN. Orchestration of angiogenesis and arterovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF). Proc Natl Acad Sci U S A 2002; 99:8219-8224.
244. 165/Angiopoietin-1 gene and endothelial progenitor cells for therapeutic neovascularization. Eur J Pharmacol 2007; 568:222-230.
245. Benest AV, Salmon AH, Wang W, Glover CP, Uney J, Harper SJ, Bates DO. VEGF and angiopoietin-1 stimulate different angiogenic phenotypes that combine to enhance functional neovascularization in adult tissue. Microcirculation 2006; 13:423-437.
246. Lu N, Xu X, Zhang M, Cao R, Bakenhielm E, Li C, et al. Combinatorial protein therapy of angiogenic and arteriogenic factors remarkably improves collaterogenesis and cardiac function in pigs. Proc Natl Acad Sci U S A 2007; 104:12140-12145.
247. Kondoh K, Koyama H, Miyaya T, Takato T, Hamadsa H, Shigematsu H. Conduction performance of collateral vessels induced by vascular endothelial growth factor or basic fibroblast growth factor. Cardiovasc Res 2004; 61:132-142.
248. Lee JS, Kim JM, Kim KL, Jang HS, Shin IS, Jeon ES, et al. Combined administration of naked DNA vectors encoding VEGF and bFGF enhances tissue perfusion and arteriogenesis in ischemic hindlimb. Biochem Biophys Res Commun 2007; 360:752-758.
249. Ye L,Haider H, Tan R, Toh WC, Law PK, Tan WB, et al. Transplantation of nanoparticle transfected skeletal myoblasts overexpressing vascular endothelial growth factor-165 for cardiac repair. Circulation 2007; 116 (Suppl I):113-120.
250. Bonaros N, Rauf R, Werner E, Schlechtor B, Rohde E, Kocher A, et al. Neoangiogenesis after combined transplantation of skeletal myoblasts and angiopoietic progenitors leads to increate cell engraftment and lower apoptosis rates in ischemic heart failure. Int Cardiovasc Thorax Surg 2008; 7:249-255.
251. Lavine KJ, Ornitz DM. Rebuilding the coronary vasculature:hedgehogas a new candidate for pharmacologic neovascularization. Trends Cardiovasc Med 2007; 17:77-83.
252. Lavine KJ, White AC, Park C, Smith CS, Choi K, Long F, et al. Fibroblast growth factor signals regulate a wave of hedgehog activation that is essential for coronary vascular development. Genes Dev 2006; 20:1651-1661.
253. Lavine KJ, Ornitz DM. Fibroblasts growth factors and hedgehogs: at the heart of the epicardial signaling center. TRENDS Genet 2007; 24:33-40.
254. Kusano KF, Pola R, Murayama T, Curry C, Kawamoto A, Iwakura A, et al. Sonic hedgehog myocardial gene therapy: tissue repair through transient reconstitution of embryonic signaling. Nat Med 2005; 11:1197-1204.
255. Bussolino F. Small molecule approaches for promoting ischemic tissue vascularization. Cardiovasc Res 2006; 99:231-233.
256. Murphy S, Larivée B, Craig KS, Williams DE, Huang XH, Abbott M, et al. Identification of sokotrasterol sulfate as a novel proangiogenic steroid. Circ Res 2006; 99:257-265.
257. Carmeliet P. VEGF gene therapy: stimulating angiogenesis or angioma-genesis? Nat Med 2000; 6:1102-1103.
258. Jain RK. Molecular regulation of vessel maturation. Nat Med 2003; 9:685-693.
259. Laflamme MA, Zbinden S, Epstein SE, Murry CE. Cell-based therapy for myocardial ischemia and infarction: pathophysiological mechanism. Ann Rev Pathol Mech Dis 2007; 2:307-339.
260. Charwat S, Gyongyosi M, Lang I, Graf S, Beran G, Hemetsberger R, et al. Role of adult bone marrow stem cells in the repair of ischemic myocardium: current state of the art. Exp Hematol 2008; 36:672-680.
261. Napoli C, Williams-Ignarro S, Byrns R, Balestrieri ML, Crimi E, Tecce MF, et al. Therapeutic targeting of the stem cell niche in experimental hindlimb ischemia. Nat Clin Pract Cardiovasc Med 2008; 5:571-579.
262. Napoli C, Maione C, Schiano C, Fiorito C, Ignarro LJ. Bone marrow cellmediated cardiovascular repair: potential of combined therapies. Trends Mol Med 2008; 13:278-286.